Agilent Technologies与Incyte合作 - Agilent Technologies与Incyte达成协议，合作开发伴随诊断产品，支持Incyte的血液学和肿瘤学产品[1] - Agilent和Incyte合作开发伴随诊断项目，Agilent将继续扩展其伴随诊断产品组合，Incyte将利用Agilent在IVD检测方面的专业知识支持临床试验和产品注册[2] - Agilent的伴随诊断部门副总裁Paul Beresford强调合作的重要性，希望通过伴随诊断的力量改变癌症治疗范式[3] - Incyte的转化医学集团副总裁Jeff Jackson表示对合作的期待，认为Agilent在伴随诊断开发方面的专业知识和商业记录令人印象深刻[3] 伴随诊断市场预测 - 伴随诊断市场预计到2030年将扩大至近140亿美元，用于指导越来越多癌症和其他慢性疾病的治疗决策[1] - 伴随诊断市场预计到2030年将达到137.4亿美元规模[4] Agilent的产品和合作伙伴 - Agilent在精准肿瘤领域拥有丰富的化学和技术组合，提供伴随诊断开发的产品和合作伙伴，如HercepTest和PDL-1 IHC 22C3[3]

The latest trading session saw Agilent Technologies (A) ending at $130.99, denoting a +0.85% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 0.07%. On the other hand, the Dow registered a gain of 0.16%, and the technology-centric Nasdaq decreased by 0.36%. Heading into today, shares of the scientific instrument maker had lost 7.08% over the past month, lagging the Computer and Technology sector's gain of 5.93% and the S&P 500's gain of 3.05% in that time. Analysts and in ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Tech ...

Over the past 80 years, the United States faced a persistent issue of in-state manufacturing decline, marked by a shift towards research and development rather than domestic production. The trend led to a significant loss of manufacturing jobs, peaking in the 2000s with a 33% decrease. However, technology is now reshaping U.S. manufacturing, offering a modern and advanced system. Investing in this upward trend, with an expected 5.2% rise in wages and benefits, can usher in a prosperous new era for American ...

To boost capabilities in protein analysis, Agilent Technologies (A) announced the launch of the Agilent ProteoAnalyzer system. The Agilent ProteoAnalyzer system is a new automated parallel capillary electrophoresis system for protein analysis that brings more efficiency, versatility and reliability in protein QC workflows by automating the separation, data processing and simplifying sample preparation steps. This way, it analyzes complex protein mixtures seamlessly. It is designed to analyze different sizes ...

Investors looking for stocks in the Electronics - Testing Equipment sector might want to consider either Fortive (FTV) or Agilent Technologies (A) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks w ...

ValeryEgorov Step one: Wide-moat stocks with 5-star and 4-star ratings Historical evidence says that while quality alone is a poor indicator of outperformance, when combined with a decent valuation filter, Morningstar’s moat rating proves to be more than useful. Based on the available data, stocks with a wide-moat rating that also fit into the 4- or 5-star category deserve to be the subject of further analysis. See the detailed explanation and the underlying evidence of our first step in this article. We fo ...

Agilent Technologies, Inc. (NYSE:A) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 12:45 PM ET Company Participants Mike McMullen - President & Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Hi. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team here at JPMorgan. I'm joined by the Agilent management team on stage as these sessions typically are, it's 40 minutes, ...

业绩总结 - 公司的业务总额为68亿美元，年复合增长率为7%[5] - 公司的利润率为27.4%，过去四年每年增长100个基点[5] - 公司的仪器业务占40%，而服务、耗材、诊断测试和软件占60%[6] - 公司在六个细分市场中竞争，其中制药是最大的市场，占总业务的36%[7] - 公司承诺实现4%至7%的核心增长，每年50至100个基点的运营利润率扩张[8] - 公司自2015年以来，营运现金流年复合增长率为17%，从每年5亿美元增长到2023年的18亿美元[13] - 公司自2015年以来投入46亿美元用于未来增长，其中30亿美元用于并购，约8%的总收入来自收购公司[14] - 公司分发18亿美元的现金股息，并进行了50亿美元的股票回购[15] 市场扩张和并购 - 公司在全球五个主要地区的业务都保持了6%至8%的增长，通过建立本地团队来推动业务[26] - Agilent CrossLab服务业务为公司带来16亿美元的业务，年复合增长率为10%，64%的收入来自年度或多年服务合同[27] - 先进材料是Agilent的长期增长市场之一，预计半导体市场也将是Agilent的长期增长市场[43] 新产品和新技术研发 - 公司正在加大对人工智能的投入，包括收购Virtual Controls，用于为客户提供AI启用的数据解释，以及在公司内部使用AI降低生产线上的检查成本[45] 负面信息 - 中国市场在2023年下降31%[88] - 中国市场在2023年下降30%[96] - 中国市场在2023年下降20%[96] - 中国市场在2023年下降中位数个位数[96] - 中国市场在2023年下降至20%[96] - 中国市场在2023年下降至30%[96]

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social, and governance (ESG) performance. “ It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s progress in reducing emissions throughout our value chain and providing innovative solutions to help our c ...